PLYMOUTH
MEETING, Pa., Dec. 12,
2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc.
(Nasdaq: INO), a biotechnology company focused on developing and
commercializing DNA medicines to help treat and protect people from
HPV-related diseases, cancer, and infectious diseases, today
announced that it intends to offer and sell shares of its common
stock and accompanying warrants to purchase shares of its common
stock, in an underwritten public offering. All of the securities in
the proposed offering will be sold by INOVIO. The proposed offering
is subject to market conditions, and there can be no assurance as
to whether or when the offering may be completed, or the actual
size or terms of the offering.
Oppenheimer & Co. Inc. and Citizens JMP are acting as joint
book-running managers for the offering. Stephens Inc. is acting as
lead manager for the offering.
A shelf registration statement relating to the shares of common
stock and accompanying warrants offered in the offering described
above was filed with the Securities and Exchange Commission (SEC)
on November 9, 2023 and declared
effective by the SEC on January 31,
2024. The offering will be made only by means of a written
prospectus and prospectus supplement that form a part of the
registration statement. A preliminary prospectus supplement and
accompanying prospectus relating to and describing the terms of the
proposed offering will be filed with the SEC and will be available
on the SEC's website at www.sec.gov. Copies of the preliminary
prospectus supplement and the accompanying prospectus, when
available, may also be obtained by contacting: Oppenheimer &
Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad
Street, 26th Floor, New York, NY
10004, by telephone at (212) 667-8055, or by email
at EquityProspectus@opco.com; or Citizens JMP Securities, LLC,
600 Montgomery Street, Suite 1100, San
Francisco, California 94111, by telephone at (415) 835-8985,
or by email at syndicate@jmpsecurities.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy the securities being offered, nor
shall there be any sale of the securities being offered in any
state or other jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other
jurisdiction.
About INOVIO
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to help treat and protect people from
HPV-related diseases, cancer, and infectious diseases. INOVIO's
technology optimizes the design and delivery of innovative DNA
medicines that teach the body to manufacture its own
disease-fighting tools.
Forward-Looking Statements
This release contains or may imply "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933, as
amended, Section 21E of the Securities Exchange Act of 1934, as
amended, and the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are not based on historical fact
and include, but are not limited to, statements regarding INOVIO's
anticipated public offering, including the completion of the public
offering on the anticipated terms, if at all. Any forward-looking
statements are based on management's current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to,
risks and uncertainties related to market conditions and
satisfaction of customary closing conditions related to the
proposed public offering. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled "Risk Factors"
in INOVIO's Annual Report on Form 10-K for the year ended
December 31, 2023, INOVIO's Quarterly
Report on Form 10-Q for the quarter ended September 30, 2024 and in other filings that
INOVIO makes with the SEC from time to time. There can be no
assurance that any of the forward-looking information provided
herein will be proven accurate. These forward-looking statements
speak only as of the date hereof and INOVIO undertakes no
obligation to update forward-looking statements, and readers are
cautioned not to place undue reliance on such forward-looking
statements.
Contacts
Media: Jennie Willson (267)
429-8567 jennie.willson@inovio.com
Investors: Peter Vozzo, ICR
Healthcare, 443-213-0505 peter.vozzo@icrhealthcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inovio-announces-proposed-public-offering-302330740.html
SOURCE INOVIO Pharmaceuticals, Inc.
